Merck reported second-quarter revenue surpassing Wall Street expectations, driven by strong sales of its cancer drug Keytruda and other treatments. Adjusted earnings per share also exceeded expectations. The company raised its full-year sales forecast slightly but lowered its profit guidance due to acquisition charges. Keytruda sales rose 16%, while sales for its HPV vaccine were nearly flat. The newly launched Winrevair and Capvaxive showed promising starts.
